Is trofinetide FDA-approved, and what does the research show?

What is trofinetide?

Trofinetide is the active ingredient in Daybue and Daybue Stix, two prescription medicines for Rett syndrome ². It is a small synthetic molecule, an analog (a designed variant) of glycine-proline-glutamate, or GPE ¹. GPE is a tripeptide, a chain of three amino acids, the building blocks of proteins ¹. It occurs naturally in the brain, where enzymes cut it from a larger protein, insulin-like growth factor 1 (IGF-1) ¹. The authors of the main trial write that trofinetide "was designed to improve the poor pharmacokinetic profile of GPE," meaning how the body absorbs and clears it ¹.

Rett syndrome is "a rare, genetic neurodevelopmental disorder," a condition of how the brain develops ¹. Children seem to develop normally for about six months, then miss milestones between 6 and 18 months ¹. Between 12 and 30 months they lose hand skills and spoken language ¹.

Repetitive hand movements, seizures, irregular breathing while awake, and stomach and bowel problems are common ¹. Almost all cases come from a new, uninherited mutation in a gene on the X chromosome called MECP2 ¹. The condition mainly affects females, about 1 in 10,000 to 15,000 girls born alive ¹.

Is trofinetide FDA-approved?

Yes, as a prescription medicine for one condition. FDA approved Daybue (trofinetide) oral solution on March 10, 2023, under new drug application (NDA) 217026 ³. Its marketing status is "Prescription" as of November 9, 2026, the date of the Drugs@FDA record's data ³.

Daybue Stix is a second product, a powder for oral solution ², ⁴. FDA approved it on December 11, 2025, under NDA 219884 ⁴. It too is listed as "Prescription" as of November 9, 2026, the date of that record's data ⁴. Drugs@FDA classes its application as "Type 3 - New Dosage Form," a new form of a drug already approved ⁴.

The label says both products "are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older" ². For a reader, the status means two things. Trofinetide requires a clinician's prescription, and the cartons shown on the label are marked "Rx only" ². And its label covers Rett syndrome and no other condition ². The label's patient section adds, "It is not known if DAYBUE or DAYBUE STIX is safe and effective in children under 2 years of age" ².

See the FDA status of every peptide, updated weekly.

How does trofinetide work?

The label says, "The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown" ². The reasoning behind the drug starts with the gene. MECP2 carries the instructions for a protein, MeCP2, that binds DNA and helps regulate other genes ¹. A shortage of it "results in abnormal neuronal maturation and plasticity," the growth of nerve cells and their ability to rewire ¹.

Studied in animals: in mice bred to lack Mecp2, GPE "partially reversed RTT-like symptoms, improved survival and enhanced synaptic morphology and function" ¹. RTT is the paper's short form for Rett syndrome, and synapses are the junctions between nerve cells ¹. That finding comes from mice given GPE, the natural fragment, not from people given trofinetide ¹.

What does the research show?

The label's one placebo-controlled trial is called Study 1 there and LAVENDER in its published report ¹, ². It tested Daybue, the oral solution ². It was a phase 3 study, the large, late trial stage that precedes an approval ¹. Two phase 2 studies came before it ¹.

Studied in people: a randomized, double-blind, placebo-controlled trial of 187 girls and women aged 5 to 20 with Rett syndrome ¹, ². Randomized means chance decided who received the drug ¹. Double-blind means that neither the families nor the clinicians knew who received it ¹. Every participant had typical Rett syndrome with "a documented disease-causing mutation in the MECP2 gene" ².

For 12 weeks, 93 participants received trofinetide and 94 received placebo, twice a day, at 21 sites in the United States ¹. Seventy of the 93 on trofinetide (75.3 percent) completed the study, as did 85 of the 94 on placebo (90.4 percent) ¹.

The trial had two co-primary measures, its main yardsticks ². The first was the Rett Syndrome Behaviour Questionnaire (RSBQ), a 45-item form the caregiver completes ². It is scored from 0 to 90, and a lower score means milder symptoms ². It covers breathing, hand movements, repetitive behaviors, night-time behaviors, vocalizations, facial expressions, eye gaze and mood ².

Both groups started near 44 points ². After 12 weeks the score had fallen by 4.9 points with trofinetide and by 1.7 points with placebo ¹, ². Those figures are least-squares means, averages adjusted by the trial's statistical model ².

The label gives the difference as -3.2 points, with a 95 percent confidence interval of -5.7 to -0.6 (p = 0.018) ². The paper gives it as -3.1 points over the same interval ¹. The trial's registry record and FDA's clinical review also give -3.1 ⁵, ⁶. A confidence interval is the range in which the true difference probably lies, and a p-value this small marks a result unlikely to be chance.

The second measure was the Clinical Global Impression-Improvement scale (CGI-I) ². On it a clinician rates change from 1, "very much improved," to 7, "very much worse" ². At week 12 the mean score was 3.5 with trofinetide and 3.8 with placebo ¹, ². The difference was -0.3, with a 95 percent confidence interval of -0.5 to -0.1 (p = 0.003) ².

A key secondary measure tracked social communication on a 13-item caregiver checklist, scored from 0 to 26, where a higher score is better ¹. The score changed by -0.1 with trofinetide and by -1.1 with placebo ¹. The difference was 1.0 in favor of trofinetide, with a 95 percent confidence interval of 0.3 to 1.7 ¹.

The authors describe the effects as medium in size and "clinically meaningful" ¹. In a post hoc analysis, one chosen after the trial, they counted participants with a CGI-I score of 3 or lower, nearer the scale's "improved" end, at week 12 ¹. That was 37.7 percent of the trofinetide group and 15.2 percent of the placebo group ¹. On the trial's registered scale, a score of 3 means "minimally improved" ⁵. Acadia Pharmaceuticals, which markets Daybue, sponsored the study ¹, ².

The trial left questions open. It enrolled no males, no one under 5 or over 20, and no one without a documented MECP2 mutation, and the authors list these as limitations ¹. The label's use in children aged 2 to 4 rests on Study 1 and on "pharmacokinetic and safety data in 15 pediatric patients 2 to 4 years of age" ². Pharmacokinetic data are measurements of drug levels in the body. Those 15 children were in an open-label study, one with no placebo group, in which everyone knew the drug was given ².

Across controlled and uncontrolled trials, 260 patients aged 2 to 40 took Daybue ². Of them, 92 were treated for more than a year and 44 for more than two years ². The only placebo-controlled study on the label lasted 12 weeks ². Neither the label nor the trial paper reports any study of trofinetide for weight loss, metabolism, muscle, aging or athletic performance ¹, ².

What are the side effects?

Diarrhea and vomiting are the most common, by the label ². In Study 1, diarrhea occurred in 82 percent of patients on trofinetide and 20 percent on placebo ². Vomiting occurred in 29 percent and 12 percent ². The two products share one label, and its trial figures were recorded in patients treated with Daybue, the oral solution ².

The label's table lists six more reactions, each more frequent with trofinetide than with placebo ². They are fever (9 percent with trofinetide and 4 percent with placebo), seizure (9 and 6), anxiety (8 and 1) and decreased appetite (8 and 2) ². Fatigue (8 and 2) and nasopharyngitis, the common cold (5 and 1), complete the table ². All of these figures come from girls and women aged 5 to 20 with Rett syndrome ².

The label gives its contraindications as "None" ². It carries three warnings, on diarrhea, weight loss and vomiting ².

On diarrhea, the label says, "Most patients experience diarrhea during treatment with DAYBUE" ². Counting Study 1 together with long-term studies, 85 percent of patients treated with Daybue had it ². In that pooled count, it persisted or came back in 49 percent despite dose changes or antidiarrheal medicine ². It was "of mild or moderate severity in 96% of cases" ². The label's instruction for severe diarrhea or suspected dehydration is to "Interrupt, reduce dose, or discontinue" the drug ².

On weight loss, the finding is a harm the label warns of, not a benefit. "In Study 1, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo" ². Those patients were girls and women aged 5 to 20 with Rett syndrome ². The label tells prescribers to "Monitor weight" and sets out steps to take "if significant weight loss occurs" ². In the long-term studies, 2.2 percent of patients stopped treatment because of weight loss ².

On vomiting, the label says, "Patients with Rett syndrome are at risk for aspiration and aspiration pneumonia" ². Aspiration is vomit getting into the lungs, and aspiration pneumonia is the lung infection it can cause ². Both "have been reported following vomiting in patients being treated with DAYBUE," and the label lists them again among reports made since approval ².

Some patients stopped the drug. The label counts 18 patients receiving Daybue (19 percent) whose adverse reactions led to withdrawal from Study 1, most often diarrhea (15 percent) ². The trial paper counts 16 of 93 on trofinetide (17.2 percent), 12 (12.9 percent) for diarrhea, against 2 of 94 on placebo (2.1 percent) ¹. FDA's clinical reviewer counted two more withdrawals for diarrhea, logged as non-compliance: 18 of 93 (19.4 percent), 14 for diarrhea, against 2 of 94 on placebo, none for diarrhea ⁶.

No deaths were reported in the trial ¹. Serious adverse events occurred in three participants (3.2 percent) in each group ¹. Small, transient changes in alanine aminotransferase, a liver enzyme, were reported in 7 of 92 participants on trofinetide and 3 of 93 on placebo ¹.

The label adds cautions for particular patients. It calls trofinetide "a weak inhibitor of CYP3A and an inhibitor of P-gp," two of the body's routes for clearing other medicines ². So it can raise blood levels of some medicines taken by mouth, and the label tells prescribers to "Closely monitor patients" who take sensitive ones ². The drug is "substantially excreted by the kidney," and it is "not recommended for patients with severe renal impairment," meaning severely reduced kidney function ².

"There are no adequate data on the developmental risks associated with the use of DAYBUE or DAYBUE STIX in pregnant women," the label says ². It has no information on whether the drug passes into breast milk ². Safety and effectiveness in children under 2 "have not been established," and the clinical studies included no one aged 65 or older ². In the 15 children aged 2 to 4, adverse reactions "were similar to those reported" in Study 1 ².

In sport

Trofinetide is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ⁷.

What JumpstartMD offers

JumpstartMD does not prescribe trofinetide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.